- Home
- TARS
as 11-15-2024 4:00pm EST
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $54.20 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.60 - $52.99 | Next Earning Date: | 11-13-2024 |
| Revenue: | $129,621,000 | Revenue Growth: | 801.96% |
| Revenue Growth (this year): | 852.6% | Revenue Growth (next year): | 74.21% |
Latest Tarsus Pharmaceuticals Inc. News
TARS Breaking Stock News: Dive into TARS Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Tarsus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
MT Newswires
3 days ago
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating
GuruFocus.com
3 days ago
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ...
Zacks
4 days ago
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
MT Newswires
4 days ago
Tarsus Pharmaceuticals Q3 Loss Narrows, Revenue Surges
GlobeNewswire
4 days ago
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
GlobeNewswire
4 days ago
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
Zacks
10 days ago
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Compare TARS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TARS Tarsus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.